COMP <GO>
VRCA vs JNJ // DIVIDEND YIELD & FCF PAYOUT SAFETY
Verrica Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: VRCA 1
— JNJ 6
■ METRIC PARITY
LAST: $3.35 (-2.05%) • MKT CAP: $58.8M
dividend-safety
0.00%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRCA VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VRCA | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 2.97% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -34.20% | 34.70% | -68.90 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -50.30% | 28.50% | -78.80 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 6.00% | +174.00 | VRCA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.59 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.1 | 62.1 | -28.00 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $58.8M | $662.49B | -$662.43B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VRCA REV | JNJ REV | VRCA GROSS % | JNJ GROSS % | VRCA FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $35.6M | $94.19B | — | 67.9% | -$17.6M | $19.70B |
| FY 2024 | $7.6M | $88.82B | 65.6% | 69.1% | -$61.0M | $19.84B |
| FY 2023 | $5.1M | $85.16B | — | — | -$38.6M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRCA // BETA —
JNJ // BETA 1.08